Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors

Gynecologic Oncology

Volumn 114, Issue 3, 2009, Pages 431-436

  Tao, Xia ^a   Sood, Anil K ^a   Deavers, Michael T ^a   Schmeler, Kathleen M ^a   Nick, Alpa M ^a   Coleman, Robert L ^a   Milojevic, Ljiljana ^a   Gershenson, David M ^a   Brown, Jubilee ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Bevacizumab; Granulosa cell tumor; Ovarian cancer; Stromal ovarian tumor; Targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CD31 ANTIGEN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; LEUPRORELIN; NAVELBINE; PACLITAXEL; TOPOTECAN; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DENSITY; DRUG FATALITY; FEMALE; GENE OVEREXPRESSION; GRANULOSA CELL TUMOR; HEMATOLOGIC TOXICITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; MICROVESSEL DENSITY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY TUMOR; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECURRENT CANCER; SEX CORD TUMOR; SIDE EFFECT; SINUSITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GRANULOSA CELL TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 67651160319     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.04.021     Document Type: Article

References (27)

1. Bjorkholm E., and Silfversward C. Prognostic factors in granulosa-cell tumors. Gynecol. Oncol. 11 (1981) 261-274
2. Evans III A.T., Gaffey T.A., Malkasian Jr. G.D., and Annegers J.F. Clinicopathologic review of 118 granulosa and 82 theca cell tumors. Obstet. Gynecol. 55 (1980) 231-238
3. Fox H., Agrawal K., and Langley F.A. A clinicopathologic study of 92 cases of granulosa cell tumor of the ovary with special reference to the factors influencing prognosis. Cancer 35 (1975) 231-241
4. Schumer S.T., and Cannistra S.A. Granulosa cell tumor of the ovary. J. Clin. Oncol. 21 (2003) 1180-1189
5. Clement P.B., and Young R.H. Sex cord-stromal and steroid cell tumors. In: Clement P.B., and Young R.H. (Eds). Atlas of Gynecologic Surgical Pathology. 2nd ed (2008), Saunders Elsevier, Philadelphia 386-393
6. Calaminus G., Wessalowski R., Harms D., and Gobel U. Juvenile granulosa cell tumors of the ovary in children and adolescents: results from 33 patients registered in a prospective cooperative study. Gynecol. Oncol. 65 (1997) 447-452
7. Young R.H., Dickersin G.R., and Scully R.E. Juvenile granulosa cell tumor of the ovary. A clinicopathological analysis of 125 cases. Am. J. Surg. Pathol. 8 (1984) 575-596
8. Colombo N., Sessa C., Landoni F., Sartori E., Pecorelli S., and Mangioni C. Cisplatin, vinblastine, and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary. Obstet. Gynecol. 67 (1986) 265-268
9. Gershenson D.M., Morris M., Burke T.W., Levenback C., Matthews C.M., and Wharton J.T. Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin. Obstet. Gynecol. 87 (1996) 527-531
10. Brown J., Shvartsman H.S., Deavers M.T., Burke T.W., Munsell M.F., and Gershenson D.M. The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J. Clin. Oncol. 22 (2004) 3517-3523
11. Brown J., Shvartsman H.S., Deavers M.T., Ramondetta L.M., Burke T.W., Munsell M.F., et al. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol. Oncol. 97 (2005) 489-496
12. Abu-Rustum N.R., Restivo A., Ivy J., Soslow R., Sabbatini P., Sonoda Y., et al. Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary. Gynecol. Oncol. 103 (2006) 31-34
13. J. Brown, A.K. Sood, M.T. Deavers, L. Milojevic, D.M. Gershenson. Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted? Gynecologic Oncology 2009;113:86-90.
14. Schmidt M., Kammerer U., Segerer S., Cramer A., Kohrenhagen N., Dietl J., et al. Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF. Eur. J. Obstet. Gynecol. Reprod. Biol. 139 (2008) 72-78
15. J. Brown, M.T. Deavers, A.M. Nick, L. Milojevic, D.M. Gershenson, A.K. S. Vascular endothelial growth factor overexpression and antiogenesis are prevalent and predict clinical outcome in sex cord-stromal ovarian tumors. Gynecologic Oncology 2009;112:S95.
16. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., and Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 (1983) 983-985
17. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., and Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 (1989) 1306-1309
18. Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J., et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246 (1989) 1309-1312
19. New approval for bevacizumab. http://www.fda.gov/cder/Offices/OODP/whatsnew/bevacizumab200802.htm 2004.
20. Burger R.A., Sill M.W., Monk B.J., Greer B.E., and Sorosky J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25 (2007) 5165-5171
21. Garcia A.A., Hirte H., Fleming G., Yang D., Tsao-Wei D.D., Roman L., et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J. Clin. Oncol. 26 (2008) 76-82
22. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 (2000) 205-216
23. Kamat A.A., Merritt W.M., Coffey D., Lin Y.G., Patel P.R., Broaddus R., et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin. Cancer Res. 13 (2007) 7487-7495
24. Monk B.J., Han E., Josephs-Cowan C.A., Pugmire G., and Burger R.A. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol. Oncol. 102 (2006) 140-144
25. Richardson D.L., Backes F.J., Seamon L.G., Zanagnolo V., O'Malley D.M., Cohn D.E., et al. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol. Oncol. 111 (2008) 461-466
26. Kesterson J.P., Mhawech-Fauceglia P., and Lele S. The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report. Gynecol. Oncol. (2008)
27. Grothey A., Sugrue M.M., Purdie D.M., Dong W., Sargent D., Hedrick E., et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J. Clin. Oncol. 26 (2008) 5326-5334